The first evidence of the therapeutic potential of BiKEs for NK cell immunotherapy in CLL has been provided by Feys’ group, who generated different BiKE constructs for CD19 and CD16 able to induce in vitro ADCC against primary CLL cells [244,245]. This evidence concerns the gene FCGR3A and B-cell chronic lymphocytic leukemia.